State of Peptides 2026

Key findings

• 2026 has outpaced the previous three years combined. Of 17 first FDA approvals from 2023 to 2026 among molecules we track, 10 came in 2026, against 7 in 2023 to 2025 together; 10 of the 17 are labelled peptides by their source (as of 2026-10-02 / 2026-10-03).
• Most peptides people ask about are not approved. Of 348 encyclopedia entries, 114 are FDA-approved; 103 are research-only and 35 are approved elsewhere but not in the US (as of 2026-10-03).
• Evidence is uneven. 148 entries carry our high evidence grade and 101 our low grade, mostly where human data are thin or absent.
• Sport is strict. 204 of the entries with a 2026 WADA record are prohibited, either named on the list or, by our reading, under its S0 section for unapproved substances; 54 are unsettled.
• The pipeline is large but mostly mid-stage. 331 INN-named peptides have reached phase 2 or beyond, and 97 have an active study on ClinicalTrials.gov.
• Weight loss is the largest search theme. Of 7,503 unique autocomplete suggestions collected for peptide searches, 1,021 relate to weight loss, against 209 about safety or side effects.
• Testing data are selective. The largest buyer-submitted testing aggregator we checked listed 4,367 retatrutide tests from 378 sellers; of the last 200 visible, 63 failed. Buyer-submitted results are not a random sample.

Approvals: 2026 outpaces the previous three years

The chart counts first FDA approvals of molecules Grey Peptides tracks, by year. It combines our FDA peptide table with encyclopedia entries, using each molecule's earliest dated approval, so a new formulation or generic of an older drug is not counted. It includes some proteins and one small molecule, orforglipron, labelled as such below; it is not an exhaustive count of every FDA approval (as of 2026-10-02 / 2026-10-03).

The encyclopedia: what is approved, and how good is the evidence

Grey Peptides covers 348 peptides and peptide-like compounds in depth. Their US status, as recorded on each entry with its source, splits as follows (as of 2026-10-03).

Each entry also carries our evidence grade, from reading the studies: high where randomised human trials support the main uses, low where evidence is mostly animal or cell work.

Sport: the 2026 WADA picture

For entries with a 2026 WADA Prohibited List record, the status splits as follows. 'S0, inferred' means the substance is not approved for human use anywhere, so the list's catch-all S0 section applies by our reading; our WADA hub explains each category (as of 2026-10-03).

The pipeline

Our pipeline tracker follows every INN-named peptide whose highest ChEMBL phase is 2 or more: 331 molecules, 97 with an active study on ClinicalTrials.gov and 5 with a readout date that has passed (as of 2026-10-02). Phase 4 here means the molecule has reached approval somewhere.

Across the wider Registry of 767 molecules, statuses split as follows (as of 2026-10-02).

Regulation in 2026

FDA's page of bulk substances that may present significant safety risks in compounding lists 31 substances, many of them peptides (read 2026-10-01). Our regulatory tracker records each peptide's status by jurisdiction:

The dated events we covered this year, each linked to its Wire post and primary source:

• 2026-04-02 · Foundayo (Orforglipron) Approved: The First Oral Small-Molecule GLP-1 for Weight Loss (Approval)
• 2026-04-15 · Wegovy HD Cleared in 54 Days: What the FDA's New Voucher Pathway Means for Peptide Drugs (Regulation)
• 2026-04-22 · FDA Pulls 12 Peptides Off Its 'Do Not Compound' List — What Changes, and What Doesn't (Regulation)
• 2026-05-01 · The FDA Just Proposed Ending Mass GLP-1 Compounding — Here's What It Actually Means (Regulation)
• 2026-05-04 · Ozempic Pill Reaches US Pharmacies: First Oral Peptide GLP-1 for Type 2 Diabetes (Approval)
• 2026-07-16 · FDA Staff Propose Rejecting All Seven Peptides Before Next Week's Compounding Committee (Regulation)
• 2026-07-17 · The FDA Comment Window on Compounded GLP-1s Closes July 30 — Not June 29 (Regulation)
• 2026-09-25 · PCAC Backed Six of Seven Peptides in July. Two Months Later, FDA Has Not Acted (Regulation)
• 2026-09-28 · FDA: Adding a Vitamin Does Not Stop a Compounded GLP-1 From Being a Copy (Regulation)
• 2026-09-30 · Two Peptides in Tablet Form: FDA's 2026 Approvals of Icotyde and Lipfendra (Approval)
• 2026-09-30 · FDA Approves a Second Once-Weekly Insulin: Lilly's Onswik Joins Novo's Awiqli (Approval)
• 2026-09-30 · FDA to Five Online Peptide Sellers: A 'Research Use Only' Label Does Not Decide What You Are Selling (Regulation)
• 2026-09-30 · WADA's 2027 Prohibited List Writes 'Peptides' Into Its Catch-All Ban (Regulation)
• 2026-10-01 · FDA Approves Rusfertide (Mimrylo), the First Hepcidin Mimetic for Polycythemia Vera (Approval)
• 2026-10-01 · The Gray Market Passed $100 Million On-Chain. Spending on Testing Fell to $8 a Buyer (Regulation)

Our country law pages cover enforcement in nine countries.

What people search for

For the Phase 2 content audit, we collected 816 autocomplete seed queries, yielding 7,503 unique suggestions (collected 2026-09-26). Grouped by theme, with a suggestion able to fall into more than one:

Testing

Our lab results database, built from published independent reports and not yet public as a page, holds 12 rows of published, independent results so far (updated 2026-10-01). Buyer-submitted testing is far larger but self-selected; our retatrutide testing article explains why its pass rates cannot be read as a market average.

Methodology

Every figure on this page is computed by a script from Grey Peptides' own source files, each of which records where its data came from and when it was read: the Registry (ChEMBL, Drugs@FDA via openFDA, UniProt), the encyclopedia dataset (labels, Drugs@FDA, PubMed and the WADA Prohibited List, each cited on its entry), the pipeline tracker (ChEMBL and ClinicalTrials.gov), the regulatory tracker, the Wire, Google autocomplete suggestions collected for our content audit, and our lab results database. The CSV lists every figure with its source file and as-of date. Counts reflect what Grey Peptides tracks; they are not a census of all peptides or all approvals. Approvals are first approvals of a molecule, not new formulations or indications. Status and evidence grades are our editorial readings of cited sources, explained on our methodology page.

Journalists and researchers may use the figures with attribution to Grey Peptides and a link to this page.